Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphoma | Preclinical | DE | 01 Apr 2020 |